Catalent Preps Early for COVID-19 Vaccine Production, an Industrial Info Market Brief
Catalent Preps Early for COVID-19 Vaccine Production, an Industrial Info Market Brief
Attachment: catalentcovid
Catalent, a leading drug contract manufacturing organization (CMO), has a $114 million expansion underway at its Bloomington, Indiana, production plant. First reported by Industrial Info in January 2019, the project launched late last year. The expansion adds 79,000 square feet of biological fill and finish capacity. When completed next year, it will help the company's alliance with Johnson & Johnson in production of an eventual COVID-19 vaccine.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Catalent Amps Up Contract Biological Manufacturing Capacity Plans to $200 m...
- Medical Devices & Equipment Sector Brings Billions in Spending to the U.S.
- Novo Nordisk Spends $11 Billion to Make More Weight Loss Drugs
- EU Adds New COVID-19 Manufacturing Capacity
- Catalent to Spend $100 Million on Italian Drugs Plant